InvestmentPitch Media Video Discusses FSD Pharma's Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS
Stock Information for FSD Pharma Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About FSD Pharma Inc.
InvestmentPitch Media Video Discusses FSD Pharma's Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis